Published: 2020-04-16 Oneness Biotech announced yesterday (15th) that it has reached a licensing agreement with Denmark’s LEO Pharma with regard to the new antibody drug technology FB825 which was developed by Oneness and licensed amounted US$530 million (approximately NT$16 billion). Oneness mentioned that phase II a (2a) clinical trial for atopic dermatitis will be implemented in the U.S. and expected to...Read More